LINCOMYCIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lincomycin Hydrochloride, and what generic alternatives are available?
Lincomycin Hydrochloride is a drug marketed by Arthur Grp, Gland Pharma Ltd, Micro Labs, Slate Run Pharma, Slayback, and Xgen Pharms. and is included in six NDAs.
The generic ingredient in LINCOMYCIN HYDROCHLORIDE is lincomycin hydrochloride. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the lincomycin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lincomycin Hydrochloride
A generic version of LINCOMYCIN HYDROCHLORIDE was approved as lincomycin hydrochloride by XGEN PHARMS on June 4th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LINCOMYCIN HYDROCHLORIDE?
- What are the global sales for LINCOMYCIN HYDROCHLORIDE?
- What is Average Wholesale Price for LINCOMYCIN HYDROCHLORIDE?
Summary for LINCOMYCIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 133 |
Clinical Trials: | 3 |
Patent Applications: | 1,114 |
DailyMed Link: | LINCOMYCIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for LINCOMYCIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tan Tock Seng Hospital | Phase 4 |
Menzies School of Health Research | Phase 4 |
The Peter Doherty Institute for Infection and Immunity | Phase 4 |